TY  - GEN
AU  - Karg,M V
AU  - Bosch,A
AU  - Kannenkeril,D
AU  - Striepe,K
AU  - Ott,C
AU  - Schneider,M P
AU  - Boemke-Zelch,F
AU  - Linz,P
AU  - Nagel,A M
AU  - Titze,J
AU  - Uder,M
AU  - Schmieder,R E
TI  - SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
SN  - 1475-2840
PY  - 2019///0128
KW  - Aged
KW  - Benzhydryl Compounds
KW  - adverse effects
KW  - Blood Glucose
KW  - drug effects
KW  - Blood Pressure
KW  - Cross-Over Studies
KW  - Diabetes Mellitus, Type 2
KW  - blood
KW  - Double-Blind Method
KW  - Female
KW  - Germany
KW  - Glucosides
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Muscle, Skeletal
KW  - Prospective Studies
KW  - Skin
KW  - Sodium
KW  - metabolism
KW  - Sodium-Glucose Transporter 2
KW  - Sodium-Glucose Transporter 2 Inhibitors
KW  - Time Factors
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1186/s12933-017-0654-z
ER  -